The terms, per the grant. On January 26, 2021, Agilent Technologies was issued US10900034B2, "Guide RNA with chemical modifications." The dense CPC stack — C12N 15/111, plus a long series of C12N 2310 modification tags (2310/321, 2310/322, 2310/3231 and more) — describes the specific chemistry that makes a guide RNA stable and effective enough to use therapeutically.

Why a deals desk separates this layer: in gene editing, the drug companies make the medicines, but the reagent and tooling suppliers own IP that the drug companies must use or license. Chemically modified guides are a classic picks-and-shovels asset — value that accrues to a supplier through reagent sales and licensing rather than through any single clinical program.

“The present invention relates to modified guide RNAs and their use in clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems.”— U.S. Patent No. 10,900,034 source

The structure point: tooling IP supports a fundamentally different royalty than drug IP. It can collect a small, broad royalty across the whole field, insulated from any one program's clinical risk. For a teardown, that is a more diversified, lower-variance value stream than a single-asset royalty.

What the grant does not promise: a clinical result or a marketed product — that is not what tooling IP is for. It is an exclusivity claim on a chemistry, and its value depends on how widely that chemistry is used across the field.

The takeaway: when tearing down gene-editing economics, do not stop at the drug grants — read the reagent and modified-guide IP, because that is where broad, program-agnostic royalties live. Agilent's January 2021 modified-guide grant is a dated example of the tooling layer.